DOI: 10.1001/jamaoncol.2017.3462
,
,
PMID: 29145547
Issn Print: 2374-2437
Publication Date: 2018/01/01
Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma
Andrew J. Sinnamon; Madalyn G. Neuwirth; Phyllis A. Gimotty; Tara C. Gangadhar; Ravi K. Amaravadi; Lynn M. Schuchter; Giorgos C. Karakousis
Author Information: Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia
Checking for direct PDF access through Ovid |
Abstract
Abstract unavailable for this article.